Abstract |
A very simple, low dose, orally administered regime (10 to 15 mg of fluoximesterone + 6 mg of deflazacort daily for periods of 1 to several months) resulting in mild-acceptable toxicity (essentially some weight gain) determined subjective improvement in 2/3 of 34 evaluable patients (out of 36 treated) and an objective measurable tumor reduction in 1/3, although most patients had been previously treated with chemotherapy and hormone treatment and proved primarily or secondarily refractory. The receptor status at the beginning of fluoximesterone+deflazacort treatment was not known, except in one negative-receptor patient, who responded to the combination after becoming resistant to tamoxifen (see photo). In some patients the condition of hormone refractoriness would suggest a no-treatment policy, but a trial with this regime is always convenient as it may improve both duration and quality of life.
|
Authors | A Fornasiero, E Ferrazzi, S M Aversa, O Daniele, C Ghiotto, V C Sileni, P De Besi, M V Fiorentino |
Journal | Tumori
(Tumori)
Vol. 78
Issue 4
Pg. 266-9
(Aug 31 1992)
ISSN: 0300-8916 [Print] United States |
PMID | 1466084
(Publication Type: Journal Article)
|
Chemical References |
- Pregnenediones
- Fluoxymesterone
- deflazacort
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy)
- Female
- Fluoxymesterone
(administration & dosage, adverse effects)
- Humans
- Middle Aged
- Pregnenediones
(administration & dosage, adverse effects)
|